Extended Data Fig. 7: Effects of doxorubicin on hCO.
From: Scalable production of human cortical organoids using a biocompatible polymer
(a) Organoid growth ratio of hCO treated with Doxo for 8 days or DMSO or H2O treated hCO; n = 12 organoids for control (DMSO), n = 12 organoids for control (H2O), n = 14 organoids for Doxo treated hCO from 3 hiPS cell lines. One-way ANOVA: F = 2.310(2, 35), P = 0.69 with Tukey’s multiple comparisons test for control (DMSO) versus control (H2O), **P = 0.0013 for control (DMSO) versus Doxo, ***P = 0.0001 for control (H2O) versus Doxo. Data show mean ± s.e.m. (b) Organoid growth ratio of hCO treated with Doxo per hiPS cell lines from data in (e); n = 4 organoids for each condition (KOLF2.1 J and 1205-4), n = 4 organoids for control and n = 6 organoids for Doxo-treated hCO (1208-2); two-tailed unpaired t-test, **P = 0.0058 for KOLF2.1 J, ****P < 0.0001 for 1208-2, and ***P = 0.0003 for 1205-4. Data show mean ± s.e.m. (c) Organoid growth ratio of hCO treated with Doxo added to control medium or XG-supplemented medium; n = 12 organoids for Doxo (Control), n = 14 organoids for Doxo (XG) including 3 hiPS cell lines. Two-tailed unpaired t-test, P = 0.08. Data show mean ± s.e.m.
